Nikolaenko Liana, Nademanee Auayporn
Department of Hematology/Bone Marrow Transplant, City of Hope, Duarte, CA 91010, USA.
Future Oncol. 2020 Oct;16(29):2273-2282. doi: 10.2217/fon-2020-0026. Epub 2020 Jul 17.
Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is US FDA approved for treatment of classic Hodgkin lymphoma (cHL) after progression or relapse of at least two prior lines of chemotherapy or autologous stem cell transplantation, as consolidation therapy after autologous stem cell transplantation for high-risk patients and as a front-line therapy for previously untreated, advanced-stage cHL in combination with chemotherapy. BV is a well-tolerated treatment in previously heavily pretreated relapsed/refractory cHL and in treatment-naive patients. BV use, in combination with other antineoplastic agents for cHL, is under investigation in multiple prospective clinical trials.
本妥昔单抗（BV）是一种靶向CD30的抗体药物偶联物，已获美国食品药品监督管理局（US FDA）批准，用于治疗至少经过两线先前化疗或自体干细胞移植进展或复发后的经典霍奇金淋巴瘤（cHL），作为高危患者自体干细胞移植后的巩固治疗，以及作为先前未治疗的晚期cHL与化疗联合的一线治疗。BV在先前接受过大量预处理的复发/难治性cHL患者和初治患者中是一种耐受性良好的治疗方法。BV与其他用于cHL的抗肿瘤药物联合使用正在多项前瞻性临床试验中进行研究。
